Literature DB >> 31399813

[New slow-release buprenorphine formulations for optimization of opioid substitution].

Michael Soyka1,2, Oliver Pogarell3.   

Abstract

Opioid maintenance treatment with methadone or buprenorphine is an established first-line treatment for opioid dependence. In addition to the novel weekly and monthly subcutaneously injectable buprenorphine depot CAM 2038 (Buvidal®), which is already available in Germany, two other long-acting buprenorphine formulations may be introduced in the near future: the monthly depot formulation RBP-6000 (Sublocade™) and a 6-month buprenorphine depot implant (Probuphine™). Basic pharmacological and clinical data of these three medications are given and possible clinical applications are discussed.

Entities:  

Keywords:  Opioid dependence; Opioid maintenance therapy; Opioids; Pharmacology; Safety

Mesh：

Substances：

Year:  2019        PMID： 31399813     DOI： 10.1007/s00115-019-0783-6

Source DB:  PubMed          Journal:  Nervenarzt        ISSN： 0028-2804            Impact factor:   1.214


  41 in total

1.  A controlled trial of buprenorphine treatment for opioid dependence.

Authors:  R E Johnson; J H Jaffe; P J Fudala
Journal:  JAMA       Date:  1992-05-27       Impact factor: 56.272

Review 2.  Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification.

Authors:  Laura Amato; Silvia Minozzi; Marina Davoli; Simona Vecchi
Journal:  Cochrane Database Syst Rev       Date:  2011-09-07

Review 3.  Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence.

Authors:  Laura Amato; Silvia Minozzi; Marina Davoli; Simona Vecchi
Journal:  Cochrane Database Syst Rev       Date:  2011-10-05

Review 4.  Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM).

Authors:  R L Deamer; D R Wilson; D S Clark; J G Prichard
Journal:  J Addict Dis       Date:  2001

5.  Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence.

Authors:  Jason White; James Bell; John B Saunders; Paul Williamson; Maria Makowska; Aaron Farquharson; Katherine L Beebe
Journal:  Drug Alcohol Depend       Date:  2009-04-28       Impact factor: 4.492

Review 6.  Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification.

Authors:  Laura Amato; Silvia Minozzi; Marina Davoli; Simona Vecchi; Marica Mf Ferri; Soraya Mayet
Journal:  Cochrane Database Syst Rev       Date:  2008-10-08

7.  A meta-analytic review of psychosocial interventions for substance use disorders.

Authors:  Lissa Dutra; Georgia Stathopoulou; Shawnee L Basden; Teresa M Leyro; Mark B Powers; Michael W Otto
Journal:  Am J Psychiatry       Date:  2008-01-15       Impact factor: 18.112

8.  A randomized, open-label trial comparing methadone and Levo-Alpha-Acetylmethadol (LAAM) in maintenance treatment of opioid addiction.

Authors:  J Wolstein; M Gastpar; T Finkbeiner; C Heinrich; R Heitkamp; T Poehlke; N Scherbaum
Journal:  Pharmacopsychiatry       Date:  2009-01-19       Impact factor: 5.788

9.  Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers.

Authors:  Mark K Greenwald; Chris-Ellyn Johanson; David E Moody; James H Woods; Michael R Kilbourn; Robert A Koeppe; Charles R Schuster; Jon-Kar Zubieta
Journal:  Neuropsychopharmacology       Date:  2003-11       Impact factor: 7.853

10.  Levo-alpha-acetylmethadol (LAAM) induced QTc-prolongation - results from a controlled clinical trial.

Authors:  H Wieneke; H Conrads; J Wolstein; F Breuckmann; M Gastpar; R Erbel; Norbert Scherbaum
Journal:  Eur J Med Res       Date:  2009-01-28       Impact factor: 2.175
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.